Tech BusinessStart-ups & Funding
Isomorphic Labs lands $5 billion Series C funding for AI-designed drug clinical trials
Isomorphic Labs funding secured $5 billion in Series C funding to advance candidates toward clinical trials on 17 November 2026. The round brings together existing backers and new investors to expand the company's medicine pipeline.

Key takeaways
- Isomorphic Labs obtained $5 billion in a Series C round
- The round was led by Greenoaks and Sequoia Capital with Andreessen Horowitz joining as a new investor
- The company's AI drug-design programme has shown positive data in oncology and immunology
- Deals with Eli Lilly, Novartis and Johnson & Johnson underline the platform’s industry relevance
In this article
Funding round overview
The Series C round will fuel Isomorphic Labs’ work on AI-designed drug candidates, targeting oncology and immunology indications. The investment supports the organisation’s expanding medicine pipeline.
Investor composition
The funding round was led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor. Alphabet’s venture arms GV and Capital G, with Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund also took part.
AI drug-design platform

Isomorphic Labs built its pipeline on a AI drug-design programme that uses simulation models to map chemistry space. The company has shown positive data in oncology and immunology.
Path to clinical trials
The new funding will enable Isomorphic Labs to expand its medicine pipeline beyond oncology and immunology. Deals with Eli Lilly, Novartis and Johnson & Johnson underline the platform’s industry relevance.
Sources
Spotted a mistake? See our corrections policy. Read how News by OnDevice works in our editorial policy.



